Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK

PURPOSE: To compare the efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK study. DESIGN: HAWK was a global, 2-year, randomised, double-masked, multicentre phase III trial in participants with neovascular age-related...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogura, Yuichiro, Jaffe, Glenn J, Cheung, Chui Ming Gemmy, Kokame, Gregg T, Iida, Tomohiro, Takahashi, Kanji, Lee, Won Ki, Chang, Andrew A, Monés, Jordi, D’Souza, Divya, Weissgerber, Georges, Gedif, Kinfemichael, Koh, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234403/
https://www.ncbi.nlm.nih.gov/pubmed/34301613
http://dx.doi.org/10.1136/bjophthalmol-2021-319090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234403/
https://www.ncbi.nlm.nih.gov/pubmed/34301613
http://dx.doi.org/10.1136/bjophthalmol-2021-319090

Ejemplares similares